Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.
A total of 38 subjects have been enrolled at sites in the U.S. and EU, up from 20 subjects on Nov. 3, the company’s prior corporate update.
There are now 38 sites open for enrollment in VTL-308 in the U.S. and EU. The company expects to open an additional 12 clinical sites and still expects to announce topline results in mid-2018.
In addition, Vital noted that a paper entitled, “Early Change in Bilirubin Level as a Surrogate for Outcome in ELAD Clinical Study of Severe Alcoholic Hepatitis,” has been accepted for oral presentation at the Asian Pacific Association for the Study of the Liver meeting in Shanghai, China on Feb. 19.
Dr. Tare Hassan, a physician investigator in the VTI-208 and VTL-308 clinical trials from the Southern California Research Center in Coronado, will present the paper.
